levofloxacin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   137 Trials   137 Trials   5343 News 


«12...1011121314151617181920...9091»
  • ||||||||||  deferoxamine / Generic mfg.
    Preclinical, Journal, Gram negative:  In vitro effects of deferoxamine on antibiotic susceptibility in Gram-negative bacteria. (Pubmed Central) -  May 24, 2024   
    The production of siderophores triggered by the increased metabolic activity of actively proliferating bacteria at the infection site may provide better results. Therefore, expanding these investigations and developing infection models through animal testing would be advantageous.
  • ||||||||||  Taigexyn (nemonoxacin) / TaiGen
    Retrospective data, Review:  Identifying the Best Initial Oral Antibiotics for Adults with Community-Acquired Pneumonia: A Network Meta-Analysis. (Pubmed Central) -  May 23, 2024   
    We observed trends toward a better clinical response and lower mortality for quinolones as empiric antibiotics for CAP, but found no conclusive evidence of any antibiotic being clearly more effective than another. More trials are needed to inform guideline recommendations on the most effective antibiotic regimens for outpatients with mild to moderate CAP.
  • ||||||||||  Retrospective data, Journal:  Treatment failure is a key factor in the development of Helicobacter pylori resistance. (Pubmed Central) -  May 23, 2024   
    The prevalence of amoxicillin, clarithromycin, levofloxacin, and metronidazole resistance would increase rapidly following first-line treatment failure, as well as the MIC values of them. Clinicians should pay great attention to the first-line treatment to cure H.?pylori infection successfully.
  • ||||||||||  levofloxacin / Generic mfg.
    Journal:  An adaptive drug-releasing contact lens for personalized treatment of ocular infections and injuries. (Pubmed Central) -  May 22, 2024   
    Our approach presents an adaptive drug-releasing contact lens responsive to reactive oxygen species (ROS) at ocular inflammation sites, synchronously releasing Levofloxacin and Diclofenac...When combined with autologous serum, this hydrophilic, flexible lens aids corneal epithelial regeneration, reducing irritation and promoting healing. In summary, this ROS-responsive drug-releasing contact lens combines antibacterial and anti-inflammatory effects, offering a promising solution for bacterial keratitis and alkali burns.
  • ||||||||||  Antibiotic Associated Acquired Hemophilia: Analysis of FAERS database (Exhibition Hall) -  May 17, 2024 - Abstract #ISTH2024ISTH_1709;    
    The top 5 antibiotics were Ciprofloxacin (24 cases), Levofloxacin (24 cases), Doxycycline (24 cases), Ceftriaxone (23 cases), and Amoxicillin (18 cases). The top 5 antibiotics ranked by signal strength were Ceftriaxone (ROR 43.3, 95%CI 28.9-64.9), Doxycycline (ROR 23.2, 95%CI 15.1-35.7), Cefuroxime (ROR 19.4 95%CI 10.7-35.2), Piperacillin/ Tazobactam (ROR 11.0 95%CI 6.0-20.0), and Amoxicillin (ROR 10.8 95%CI 7.0-16.6).
  • ||||||||||  Mycobutin (rifabutin) / Pfizer, Lupin
    Journal:  Antibiotic susceptibility pattern of Helicobacter pylori against eight antibiotics: A study from North India. (Pubmed Central) -  May 17, 2024   
    In cases of isoniazid-resistant index patients, even premature newborns may consider the use of rifampin or levofloxacin for window prophylaxis. TET, AMX, CLA, and RIF were found to be more effective antibiotics against H. pylori infections, whereas more studies are required to provide evidence on increasing resistance rate of LVFX.
  • ||||||||||  levofloxacin / Generic mfg.
    Journal, Metastases:  Carbon Dots-Inked Paper with Single/Two-Photon Excited Dual-Mode Thermochromic Afterglow for Advanced Dynamic Information Encryption. (Pubmed Central) -  May 13, 2024   
    The CDs were synthesized through thermal treatment of levofloxacin in melting boric acid with post-purification via dialysis...Moreover, leveraging the opposite emission responses of phosphorescence and TADF to temperature, CDs@Paper demonstrated TCAG with temperature-sensing capabilities across a wide temperature range. Furthermore, a CDs@Paper-based 3D code containing color and temperature information was successfully developed for advanced dynamic information encryption.
  • ||||||||||  levofloxacin / Generic mfg., norfloxacin / Generic mfg.
    Journal, Machine learning:  Application of machine learning in the study of cobalt-based oxide catalysts for antibiotic degradation: An innovative reverse synthesis strategy. (Pubmed Central) -  May 11, 2024   
    Empirical experiments validated SSA's efficacy, with degradation rates of 94% for Levofloxacin and 97% for Norfloxacin, aligning closely with predictions within a 2% margin of error. This research advances theoretical understanding and offers practical applications in material science and environmental engineering, significantly enhancing catalyst design efficiency and accuracy through the fusion of advanced machine learning techniques and optimization algorithms.
  • ||||||||||  Trial completion date, Trial initiation date, Trial primary completion date:  Tailored vs. Empirical Helicobacter Pylori Infection Treatment (clinicaltrials.gov) -  May 8, 2024   
    P4,  N=160, Not yet recruiting, 
    The difficult treatment characteristics of B. cepacia bloodstream infections mean that laboratories and clinicians should pay careful attention to drug resistance to provide a basis for their prevention and empirical treatment. Trial completion date: Apr 2025 --> Nov 2025 | Initiation date: Feb 2024 --> Sep 2024 | Trial primary completion date: Nov 2024 --> Jun 2025
  • ||||||||||  Invanz (ertapenem) / Merck (MSD)
    Transition of Intravenous to Oral Antibiotics for Gram-Negative Bacteremia in Abdominal Transplant Recipients (Poster Hall, Exhibit Hall A, Level 2) -  May 6, 2024 - Abstract #ATC2024ATC_1596;    
    The findings suggest that transitioning to oral-step down therapy may be an effective treatment approach for patient who have achieved source control and when an oral option is available based on susceptibilities. Early transition to oral step-down therapy may be associated with a decrease in the duration of hospital stay.
  • ||||||||||  Antibiograms Tailored to SOT and HSCT Recipients Can Guide Empiric Antimicrobial Therapy and Prophylaxis Practices (Poster Hall, Exhibit Hall A, Level 2) -  May 6, 2024 - Abstract #ATC2024ATC_1420;    
    Lower susceptibility rates among GPC and GNB were observed for antibiotics commonly used for prophylaxis (penicillin VK, levofloxacin, and TMP/SMX) and may be impacted by institutional prophylaxis practices. Future studies assessing impact of population-specific antibiograms on empiric therapy and antibiotic prophylaxis practices are essential.
  • ||||||||||  levofloxacin / Generic mfg., moxifloxacin intravenous / Generic mfg.
    Journal:  Xpert MTB/XDR assay: rapid TB drug resistance detection. (Pubmed Central) -  May 6, 2024   
    The Index test exhibited promising outcomes in identifying resistance to isoniazid and fluoroquinolones, surpassing the performance of the LPA. This could be valuable for promptly initiating treatment in cases of drug-resistant tuberculosis.
  • ||||||||||  Trends in and risk factors for drug resistance of in people living with HIV (Poster board: 055) -  May 2, 2024 - Abstract #AIDS2024AIDS_1198;    
    The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 23 July 2024, at 10:00 am Central European Summer Time (CEST). If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
  • ||||||||||  Lamprene (clofazimine) / Novartis
    Journal:  Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis. (Pubmed Central) -  May 2, 2024   
    We evaluated the pharmacokinetic interaction between clofazimine and isoniazid, linezolid, levofloxacin, and cycloserine, dosed as terizidone...A posteriori power size calculations predicted that our sample sizes had 97%, 90%, and 87% power at P < 0.05 to detect a 30% change in clearance of isoniazid, linezolid, and cycloserine, respectively. Although clofazimine increased the area under the curve of levofloxacin by 19%, this is unlikely to be of great clinical significance, and the lack of interaction with other drugs tested is reassuring.
  • ||||||||||  levofloxacin / Generic mfg.
    Journal:  Efflux pump effects on levofloxacin resistance in Mycobacterium abscessus. (Pubmed Central) -  May 2, 2024   
    Efflux pump inhibitors can improve the antibacterial activity of LFX against M. abscessus in vitro. The overexpression of efflux-related genes in LFX-resistant isolates suggests that efflux pumps are associated with the development of LFX resistance in M. abscessus.
  • ||||||||||  Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Preclinical, Journal:  In vitro development of resistance against antipseudomonal agents: comparison of novel ?-lactam/?-lactamase inhibitor combinations and other ?-lactam agents. (Pubmed Central) -  May 2, 2024   
    Meropenem (mean, 38-fold increase), cefepime (14.4-fold), and piperacillin-tazobactam (52.9-fold) terminal mutants displayed high minimum inhibitory concentration (MIC) values compared to those obtained after exposure to ceftolozane-tazobactam (11.4-fold) and ceftazidime-avibactam (5.7-fold)...These alterations, along with ones in mexR and amrR, provided resistance to most ?-lactams and levofloxacin but not imipenem...The data generated here suggest that there is a difference in the mechanisms selected for high-level resistance between newer ?-lactam/?-lactamase inhibitor combinations and older agents. Nevertheless, the isolates exposed to all agents displayed elevated MIC values for other ?-lactams (except imipenem) and quinolones tested mainly due to alterations in the MexAB-OprM regulators that extrude these agents.
  • ||||||||||  Gatiflox (gatifloxacin) / Orient Europharma
    Review, Journal, Adverse events:  Association Between Fluoroquinolones and Major Adverse Cardiovascular Events: A Systematic Review. (Pubmed Central) -  Apr 30, 2024   
    This systematic review emphasizes the need for cautious administration of FQs, particularly in patients with a preexisting cardiovascular condition. Routine cardiac monitoring using electrocardiograms is warranted for patients on high doses of FQs to preemptively detect the development of MACE, particularly arrhythmias.
  • ||||||||||  levofloxacin / Generic mfg., moxifloxacin intravenous / Generic mfg.
    Preclinical, Journal:  In vitro and ex vivo activity of the fluoroquinolone DC-159a against mycobacteria. (Pubmed Central) -  Apr 29, 2024   
    Besides, it was more active than MOX/LX. Moreover, no cross-resistance was evidenced between DC-159a and LX/MOX as DC-159a could inhibit Mtb and MAC strains that were already resistant to LX/MOX.DC-159a could be a possible candidate in new therapeutic regimens for MDR/ XDR-TB and mycobacterioses cases.